THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE.
long acting injectable
metabolic syndrome
olanzapine
risperidone
Journal
Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720
Informations de publication
Date de publication:
Historique:
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
Literature shows that patients taking antipsychotic medication risk developing metabolic complications. The study aims to compare the presence of the metabolic syndrome (MS) and its components in outpatients treated with long acting injectable (LAI) olanzapine and risperidone. A double-center study was performed on outpatients with psychosis, which were divided into two samples: one treated with olanzapine and another with risperidone. The following data were analyzed: age, gender, severity of psychiatric symptoms, blood pressure, waist circumference, fasting blood glucose, lipid profile, tobacco use, medication, and time intervals related to psychosis duration (pre-LAI and LAI treatment). The study included 77 patients with schizophrenia and schizoaffective disorder. MS was present in 45 (58.4%) patients. Subjects with MS and abdominal obesity had higher durations of psychosis and of LAI treatment. Patients with hypertension had a higher pre-LAI treatment interval. Risperidone was associated with higher rates of hypertension and higher values of abdominal circumference than olanzapine. The presence of MS is related to the duration of the psychosis and the time spent on LAI treatment with no differences between olanzapine and risperidone. Hypertension may be a consequence of age, disorder induced stress, or of treatment with risperidone.
Identifiants
pubmed: 32010353
doi: 10.4183/aeb.2019.342
pii: aeb.2019.342
pmc: PMC6992390
doi:
Types de publication
Journal Article
Langues
eng
Pagination
342-348Informations de copyright
©by Acta Endocrinologica Foundation.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Aust N Z J Psychiatry. 2001 Apr;35(2):196-202
pubmed: 11284901
Schizophr Res. 2008 Apr;101(1-3):266-72
pubmed: 18262771
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
pubmed: 17258085
Schizophr Res. 2008 Apr;101(1-3):273-86
pubmed: 18258416
Br J Psychiatry Suppl. 2004 Apr;47:S64-6
pubmed: 15056595
Am J Psychiatry. 2006 Jul;163(7):1132-4
pubmed: 16816213
Am J Psychiatry. 2003 Jun;160(6):1125-32
pubmed: 12777271
Circulation. 2005 Dec 13;112(24):3713-21
pubmed: 16344402
Br J Psychiatry. 2005 Dec;187:537-43
pubmed: 16319406
J Clin Psychiatry. 2002 May;63(5):425-33
pubmed: 12019668
J Clin Psychiatry. 2009 Jul;70(7):1041-50
pubmed: 19653979
Schizophr Bull. 2013 Mar;39(2):306-18
pubmed: 22207632
Am J Psychiatry. 2004 Apr;161(4):692-9
pubmed: 15056516
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Br J Psychiatry. 2005 Oct;187:366-71
pubmed: 16199797
Ther Drug Monit. 2003 Feb;25(1):46-53
pubmed: 12548144
Diabetes Care. 2004 Feb;27(2):596-601
pubmed: 14747245
Psychopharmacology (Berl). 1994 Feb;114(1):9-23
pubmed: 7531353
CNS Drugs. 2005;19 Suppl 1:1-93
pubmed: 15998156
Pharmacogenet Genomics. 2010 Sep;20(9):569-72
pubmed: 20664489
Neuropsychopharmacology. 2003 Mar;28(3):519-26
pubmed: 12629531
Neuropsychiatr Dis Treat. 2010 Jun 24;6:261-7
pubmed: 20628628
Swiss Med Wkly. 2003 Feb 8;133(5-6):63-76
pubmed: 12644960
J Psychopharmacol. 2006 Jul;20(4 Suppl):15-8
pubmed: 16785265
Br J Psychiatry Suppl. 2004 Apr;47:S67-71
pubmed: 15056596
J Clin Psychiatry. 2001;62 Suppl 7:22-31
pubmed: 11346192
Acta Endocrinol (Buchar). 2016 Apr-Jun;12(2):177-184
pubmed: 31149084
Psychiatry Res. 2005 Jun 30;135(3):217-28
pubmed: 15993949
J Clin Psychopharmacol. 2003 Apr;23(2):119-27
pubmed: 12640212
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9
pubmed: 17360666